ERα-36 has been shown to activate downstream signaling pathways through HB-EGF, SRC, EGFR, HER2, IGF-1R, and ultimately to induce the transcription of growth-promoting genes such as c-Myc and Cyclin D1, and finally to stimulate tumor cell proliferation. The gene discussed is EGFR; the disease is neoplasm.